Prothena to Report Third Quarter 2026 Financial Results on November 5

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Report Third Quarter 2026 Financial Results on November 5.

Business Wire • 4 hours ago

Prothena's Partnership Strategy: Growth Driver or Limitation?

PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.

Zacks Investment Research • Oct 20, 2026

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 8, 2026

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Zacks Investment Research • Sep 21, 2026

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.

Business Wire • Sep 9, 2026

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Aug 14, 2026

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.

Zacks Investment Research • Aug 7, 2026

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.

Business Wire • Aug 6, 2026

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $1.86 per share a year ago.

Zacks Investment Research • Aug 7, 2026

Prothena to Report Second Quarter 2026 Financial Results on August 6

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena will report its second quarter and first six months of 2026 financial results on August 6, 2026.

Business Wire • Jul 30, 2026